Objective: To determine the safety and the self-reported efficacy of botulinum toxin injections for adult spasticity in current clinical practice.
Design: A prospective observational study.
Subjects: A total of 406 adult patients with focal spasticity received of 1136 series botulinum toxin injections at Bordeaux University Hospital from January 2007 to December 2009.
Methods: Adverse events following botulinum toxin injections were reported. Their severity and the therapeutic efficacy of botulinum toxin injections were estimated with a four-point self-reporting scale (0 to 3). Latency and duration of adverse events and subjective improvement were also noted.
Results: The data of 640 series of injections were analyzed. Forty-six (7.2%) adverse events were reported, of which 36 (78%) were local. There were 18 (39%) cases of local muscular weakness with an average duration of 30.0 (SD 38.2) days, and an average severity score of 1.0 (SD 0.97). Among systemic adverse events, there were 8 (17%) cases of excessive fatigue without global muscular weakness and 2 (4%) cases of transitory generalized muscular weakness. The average subjective improvement score was 1.89 (SD 0.97) and was higher for upper, than for lower, limbs (P=0.007).
Conclusion: Self-reported adverse events following botulinum toxin injections in spasticity are rare, often benign and of short duration in current clinical practice. Botulinum toxin is considered effective by patients in treating spasticity of the upper and lower limbs.
BrashearAGordonMFElovicEKassiciehVDMarciniakCDoM. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med2002; 347: 395–400.
2.
BurbaudPWiartLDubosJLGaujardEDebelleixXJosephPA. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry1996; 61: 265–269.
3.
NaumannMAlbaneseAHeinenFMolenaersGReljaM. Safety and efficacy of botulinum toxin type A following long-term use. Eur J Neurol2006; 13(Suppl 4): 35–40.
4.
SimpsonDMBlitzerABrashearAComellaCDubinskyRHallettM. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology2008; 70: 1699–1706.
5.
BrinMFLyonsKEDoucetteJAdlerCHCavinessJNComellaCL. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology2001; 56: 1523–1528.
6.
BakheitAMWardCDMcLellanDL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry1997; 62: 198.
7.
BhatiaKPMunchauAThompsonPDHouserMChauhanVSHutchinsonM. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry1999; 67: 90–93.
8.
WisselJWardABErztgaardPBensmailDHechtMJLejeuneTM. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med2009; 41: 13–25.
9.
BakheitAMPittockSMooreAPWurkerMOttoSErbguthF. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol2001; 8: 559–565.
